The Olympia Observer
SEE OTHER BRANDS

The latest news from Washington state

The Olympia Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Olympia Observer.

Press releases published on August 6, 2025

Search.co Launches Next-Generation AI Platform for Data Extraction, Ingestion, and Intelligent Action

Search.co Launches Next-Generation AI Platform for Data Extraction, Ingestion, and Intelligent Action

New platform transforms static data into real-time decisions through enterprise-ready AI agents that do more than just chat—they execute. SEATTLE, WA, UNITED STATES, August 6, 2025 /⁨EINPresswire.com⁩/ -- Search.co, a platform developed by DEV, has …

New Book ‘Finding Wellness’ Offers Hope—and Real Solutions—for the Tired, Overwhelmed, and Discouraged

New Book ‘Finding Wellness’ Offers Hope—and Real Solutions—for the Tired, Overwhelmed, and Discouraged

Finding Wellness: Essential Articles for Healing Your Mind, Body, and Spirit is available for presale now and officially launches on September 15. SPOKANE, WA, UNITED STATES, August 6, 2025 /⁨EINPresswire.com⁩/ -- For years, Dr. Randall Hansen has heard …

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - Hagens Berman

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune ( …

Centene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over “Inflated Guidance” Pending – Hagens Berman

Centene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over “Inflated Guidance” Pending – Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 …

Sable Offshore Corp. (SOC) Hit with Lawsuit Over Alleged Misleading Statements on California Oil Restart – Hagens Berman

Sable Offshore Corp. (SOC) Hit with Lawsuit Over Alleged Misleading Statements on California Oil Restart – Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sable Offshore Corp. (NYSE: SOC) is now at the center of a securities class-action lawsuit, alleging that the company misled investors to inflate its stock price just before a major secondary offering. The …

Lockheed Martin (LMT) Faces Investor Scrutiny Over Company’s Disclosures About Aeronautics and RMS Segments’ Performance, Securities Class Action Pending -- Hagens Berman

Lockheed Martin (LMT) Faces Investor Scrutiny Over Company’s Disclosures About Aeronautics and RMS Segments’ Performance, Securities Class Action Pending -- Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Khan v. Lockheed Martin Corporation, et al., No. 1:25-cv-06197 (S.D.N.Y.) has been filed and seeks to represent investors who purchased or otherwise acquired Lockheed …

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

Sarepta Therapeutics (SRPT) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending – Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta’s medication intended for the treatment of Duchenne muscular dystrophy. …

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare …

Avista Corp. Board Declares Common Stock Dividend

Avista Corp. Board Declares Common Stock Dividend

SPOKANE, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Avista Corp.’s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.49 per share on the company’s common stock. The common stock dividend is payable September 15, 2025, to shareholders of …

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 …

Costco Wholesale Corporation Reports July Sales Results

Costco Wholesale Corporation Reports July Sales Results

ISSAQUAH, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today reported net sales of $20.89 billion for the retail month of July, the four weeks ended August 3, 2025, an increase of 8.5 …

Remitly Reports Second Quarter 2025 Results Above Outlook and Raises Full Year 2025 Outlook

Remitly Reports Second Quarter 2025 Results Above Outlook and Raises Full Year 2025 Outlook

Second quarter send volume up 40% and revenue up 34% year over year  Second quarter net income was $6.5 million and Adjusted EBITDA was $64.0 million  Board of Directors authorizes $200 million share repurchase program SEATTLE, Aug. 06, 2025 (GLOBE …

Marex Group (MRX) Faces Investor Scrutiny Amid Short Seller Accusations – Hagens Berman

Marex Group (MRX) Faces Investor Scrutiny Amid Short Seller Accusations – Hagens Berman

SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- On August 5, 2025, investors in Marex Group plc (NASDAQ: MRX) saw the price of their shares significantly decline in the wake of a critical short report accusing the company of engaging in an improper multi- …

Disarming a Hidden Killer: Predicting – and Preventing – C. diff Before It Strikes

Disarming a Hidden Killer: Predicting – and Preventing – C. diff Before It Strikes

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a leading cause of healthcare-associated infections, …

Slalom Collaborates with OpenAI to Provide ChatGPT to the Entire U.S. Federal Workforce

Slalom Collaborates with OpenAI to Provide ChatGPT to the Entire U.S. Federal Workforce

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Slalom, the global business and technology consulting company, today announced an expansion to its services partnership with OpenAI. Today, OpenAI for Government announced a new partnership with the U.S. General …

Avista Corp. Reports Financial Results for the Second Quarter of 2025, Confirms 2025 Earnings Guidance with Strong Utility Offsetting Investment Losses

Avista Corp. Reports Financial Results for the Second Quarter of 2025, Confirms 2025 Earnings Guidance with Strong Utility Offsetting Investment Losses

SPOKANE, Wash., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the second quarter of 2025. Net income and earnings per diluted share for the second quarter and year-to-date 2025 compared to the same periods …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions